{"changes":[{"companyHref":"/c/artaxbiopharma-com","date":"2026-09-25","documentUrl":"https://www.sec.gov/Archives/edgar/data/1587661/000158766126000002/primary_doc.xml","domain":"artaxbiopharma.com","fact":"latest round","name":"Artax Biopharma, Inc.","new":{"amountUsd":19000000,"date":"2024-07-31","lead":null,"type":null},"old":{"amountUsd":19000000,"date":"2024-07-31","lead":null,"type":"seed"},"publisher":"SEC EDGAR","reason":null,"retrievedAt":"2026-09-25","slug":"artaxbiopharma-com","status":"sourced","url":"https://whoraisedwhat.com/c/artaxbiopharma-com"},{"companyHref":"/c/artaxbiopharma-com","date":"2026-09-25","documentUrl":"https://www.sec.gov/Archives/edgar/data/1587661/000158766126000002/primary_doc.xml","domain":"artaxbiopharma.com","fact":"provenance:round","name":"Artax Biopharma, Inc.","new":{"publisher":"SEC EDGAR","status":"sourced","url":"https://www.sec.gov/Archives/edgar/data/1587661/000158766126000002/primary_doc.xml"},"old":{"publisher":"sec-edgar","status":"attributed","url":null},"publisher":"SEC EDGAR","reason":null,"retrievedAt":"2026-09-25","slug":"artaxbiopharma-com","status":"sourced","url":"https://whoraisedwhat.com/c/artaxbiopharma-com"}],"country":"US","description":"Artax Biopharma develops oral small-molecule Nck modulators that dampen inappropriate T-cell activation at the TCR signaling level without globally suppressing the immune system. It targets autoimmune diseases including psoriasis, atopic dermatitis, and rheumatoid arthritis. Lead asset AX-158 is a first-in-class Phase 2 program modulating Signal 1 instead of downstream cytokines.","domain":"artaxbiopharma.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"pharma","investors":[],"lat":42.365635,"lng":-71.104002,"location":"Cambridge, MA","name":"Artax Biopharma, Inc.","rounds":[{"amountQuarantined":false,"amountUsd":19000000,"currency":"USD","date":"2024-07-31","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"SEC EDGAR","retrievedAt":"2026-09-25","status":"sourced","url":"https://www.sec.gov/Archives/edgar/data/1587661/000158766126000002/primary_doc.xml"},"status":"sourced","type":null,"url":"https://www.sec.gov/Archives/edgar/data/1587661/000158766126000002/primary_doc.xml"}],"slug":"artaxbiopharma-com","sources":[{"fact":"round","publisher":"SEC EDGAR","retrievedAt":"2026-09-25","status":"sourced","url":"https://www.sec.gov/Archives/edgar/data/1587661/000158766126000002/primary_doc.xml"},{"fact":"existence","publisher":"artaxbiopharma.com","retrievedAt":"2026-05-06","status":"self-reported","url":"https://artaxbiopharma.com"},{"fact":"description","publisher":"artaxbiopharma.com","retrievedAt":"2026-05-06","status":"self-reported","url":"https://artaxbiopharma.com"}],"stage":null,"techStack":["Nginx","jQuery Migrate 3.4.1","Complianz","WordPress Block Editor","WordPress Site Editor","PHP","MySQL","wordpress .","jquery 3.7.1"],"totalRaisedUsd":19000000,"updatedAt":"2026-05-06"}